Mechanisms underlying current and future anti-obesity drugs: Trends in Neurosciences
Current Perspectives on Long-term Obesity Pharmacotherapy - Canadian Journal of Diabetes
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists | Pharmacological Reviews
Cardiovascular Effects of the New Weight Loss Agents - ScienceDirect
References in Progress and challenges in anti-obesity pharmacotherapy - The Lancet Diabetes & Endocrinology
topiramate
GUCY2C: at the intersection of obesity and cancer: Trends in Endocrinology & Metabolism
JCM | Free Full-Text | Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes | HTML
Impulsivity, compulsivity, and addiction - Vaughan & Asburys General Ophthalmology, 17th ed.
Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists | Pharmacological Reviews
Antiobesity Pharmacotherapy: New Drugs and Emerging Targets - Kim - 2014 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Anti-obesity drugs currently used and new compounds in clinical development
Summary of the mechanism of action for FDA/EMA approved anti-obesity drugs. | Download Scientific Diagram
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? - Abstract - Europe PMC
Topiramate - Harte - 2020 - Practical Diabetes - Wiley Online Library
Pharmaceutical approaches to weight management: behavioural mechanisms of action - ScienceDirect
The Use of phentermine/topiramate CR (Qsymia ® ) For Chronic Weight Management Stefanie L. Drahuschak PharmD Candidate 2014 October 14, ppt download
Diabetes & Metabolism Journal
phentermine - LOMAIRA™
Pharmacological Management of Obesity: Agents and Mechanisms of Action
Obesity | NEJM
Qsymia Results : You are here
